Cargando…
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal
Current, widely accepted guidelines for the management of HIV-associated cryptococcal meningoencephalitis (CM) recommend amphotericin B combined with flucytosine (5-FC) for ≥2 weeks as the initial induction treatment of choice. However, access to flucytosine in Africa and Asia, where disease burden...
Autores principales: | Loyse, Angela, Dromer, Françoise, Day, Jeremy, Lortholary, Olivier, Harrison, Thomas S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797641/ https://www.ncbi.nlm.nih.gov/pubmed/23788479 http://dx.doi.org/10.1093/jac/dkt221 |
Ejemplares similares
-
Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis
por: Dromer, Françoise, et al.
Publicado: (2008) -
Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D Study
por: Dromer, Françoise, et al.
Publicado: (2007) -
An Elderly Patient with Pulmonary Cryptococcosis with Mediastinal Lymphadenopathy Who Was Successfully Treated with Amphotericin B and Flucytosine
por: Fujimoto, Shusaku, et al.
Publicado: (2020) -
Clonal Population of Flucytosine-Resistant Candida tropicalis from Blood Cultures, Paris, France
por: Desnos-Ollivier, Marie, et al.
Publicado: (2008) -
Addition of Flucytosine to Fluconazole for the Treatment of Cryptococcal Meningitis in Africa: A Multicountry Cost-effectiveness Analysis
por: Shiri, Tinevimbo, et al.
Publicado: (2020)